JAK inhibitor

An arrow incrementally going up stairs before pointing straight up Blue background
Biotech

Roivant reports phase 3 autoimmune win for ex-Pfizer asset

A phase 3 trial of Priovant's brepocitinib has hit its primary endpoint, setting the Roivant biotech up to seek approval for the TYK2/JAK1 inhibitor.
Nick Paul Taylor Sep 17, 2025 7:00am
Photo of a final puzzle piece about to fit into a puzzle

Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor

Jun 23, 2025 9:47am
business targets illustration

Accropeutics' TYK2/JAK1 inhibitor scores phase 2 psoriasis win

May 21, 2025 6:25am
positive negative up down good bad mixed

Incyte posts phase 3 skin condition wins but details disappoint

Mar 17, 2025 8:12am
visual of a downward stock trend

Aclaris claims ph. 2 win for JAK inhibitor but investors spooked

Jan 10, 2024 8:35am
On target clinical trial success bullseye score

Lynk hits main goal to wrap up clean sweep of phase 2 JAK trials

Aug 23, 2023 9:55am